The content on this site is intended for healthcare professionals only
Prof Joseph Mikhael talks to ecancer following his MyKE Myeloma 2021 presentation.
He begins by saying that triple class refractory multiple myeloma is a real challenge for clinicians today in multiple myeloma. This is happening earlier and earlier in the disease course as patients are treated with more effective combinations earlier in the disease.
Prof Mikhael then goes on to talk about the various options that are available that were discussed during his session. Covering selinexor, belantamab mafodotin, melphalan flufenamide and CAR T-cell therapy.
He concludes by explaining that options for triple class refractory multiple myeloma are growing. More agents are available now than ever before and we will likely have many more in the future.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
Encouraging results using mismatched unrelated donors in stem cell transplantation
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma
